Major drugmaker GSK leverages 23andMe's consumer genomic database for its drug development strategy

September 21, 2018 | Case Study

The cost of developing a new pharmaceutical drug today and successfully bringing it to market is approximately $2.5 billion, double what it used to be a decade ago. The steep rise in costs comes despite an intense effort in recent years to bring efficiency to pharmaceutical R&D. Assessing this risk and filtering out as early as possible compounds that may not eventually get approved is essential to the pharmaceutical industry and involves checking the effectiveness of drugs as well as the likelihood of toxic events. This process can be potentially enhanced by leveraging aggregated human genomic data. 


About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978